Phacoemulsification Combined With Intravitreal Injection of Ranibizumab Prevent Postoperative Capillary Non-perfusion Zone Progress in Non-proliferative Diabetic Retinopathy

Sponsor
Ruijin Hospital
Study ID
NCT05386160
Phase
PHASE4
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 90 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

Diabetic retinopathy has been found progress in 20-70% diabetic patient after cataract phacoemulsification surgery. Intravitreal injection of anti-VEGF Ranibizumab is an important treatment for diabetic retinopathy including non-proliferative diabetic retinopathy (NPDR). However, there is no research about phacoemulsification surgery combine Intravitreal injection of Ranibizumab on diabetic retinopathy. The research focus on the effect of phacoemulsification surgery combine intravitreal injection of Ranibizumab on mild non-proliferative diabetic retinopathy and explore the reasons for differences in treatment outcomes.

Key Dates

First listed
May 23, 2022
Start date
Jul 1, 2022
Status verified
Jan 2022
Primary completion
Mar 1, 2023
Completion
Mar 1, 2023

Study Design

Enrollment
96 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: Cataract phacoemulsification combines Ranibizumab
    0.05 ml of ranibizumab was injected into the vitreous immediately after the operation
  • Active Comparator: Cataract phacoemulsification
    0.05 ml of ranibizumab was injected into the vitreous immediately after the operation

Primary Outcome Measure

capillary non-perfusion zone of non-proliferative diabetic retinopathy [ Time Frame: 1 year ]

Central Contacts

Related Studies